clinical trial · NCT04861987
A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
Advanced CancerRefractory CancerTumor GastricPCS6422 and capecitabine
brief summary
This study is an open label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are candidates for fluoropyrimidine monotherapy.
started
Jun 18, 2021
primary completion
Jun 12, 2024
completion
Sep 9, 2024
last updated
Oct 10, 2024
official title
A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of Fixed-dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol